Private company
Nuvalent, Inc.
We are a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer.2
Last updated Oct 19, 2026.
Overview
-$425.4MNet income, fiscal 20253
- IndustryPharmaceutical Preparations2
- HeadquartersWilmington, United States2
- Incorporated inDE4
- Business addressOne Broadway, 14Th Floor, Cambridge, Ma 021424
- Filer categoryLarge accelerated filer4
- Legal formCorporation2
- LEI529900RZ62O2T6LNQS602
- StatusActive2
- LEI statusIssued and current2
- Registered addressc/o THE CORPORATION TRUST COMPANY, CORPORATION TRUST CENTER 1209 ORANGE ST, 19801 Wilmington, United States2
- Registered withDivision of Corporations, Department of State, 62035742
See how the biggest companies compare on our leaderboards
We are a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. We leverage our team’s deep expertise in chemistry and structure-based drug design to develop innovative small molecules that are designed with the aim to overcome the limitations of existing therapies for clinically proven kinase targets.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-34.1%Return on equity6
Financial statements
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Research and development | $15.4M7 | $35.6M8 | $63.7M9 | $113.2M6 | $217.8M6 | $307.0M6 | |
| Operating expenses | $45.8M8 | $86.1M9 | $149.5M6 | $280.4M6 | $414.3M6 | ||
| Operating income | -$16.9M7 | -$45.8M8 | -$86.1M9 | -$149.5M6 | -$280.4M6 | -$414.3M6 | |
| Income before tax | -$81.9M9 | -$126.2M6 | -$260.0M6 | -$424.8M6 | |||
| Income tax | $09 | $06 | $764.0K6 | $585.0K6 | |||
| Net income | -$14.6M7 | -$46.3M8 | -$81.9M9 | -$126.2M6 | -$260.8M6 | -$425.4M3 | |
| Earnings per share | -$5.087 | -$2.138 | -$1.659 | -$2.176 | -$3.936 | -$5.856 | |
| Earnings per share (diluted) | -$5.087 | -$2.138 | -$1.659 | -$2.176 | -$3.936 | -$5.856 | |
| Shares (weighted, basic) | 21.8M shares8 | 49.7M shares9 | 58.2M shares6 | 66.4M shares6 | 72.7M shares6 | ||
| Shares (weighted, diluted) | 21.8M shares8 | 49.7M shares9 | 58.2M shares6 | 66.4M shares6 | 72.7M shares6 |
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash | $3.0M7 | $10.3M7 | $68.5M8 | $241.8M12 | $335.4M9 | $145.7M6 | $261.7M6 |
| Current assets | $10.6M7 | $290.6M8 | $478.0M12 | $726.5M9 | $1.1B6 | $1.4B6 | |
| Total assets | $10.6M7 | $293.8M8 | $482.5M12 | $732.4M9 | $1.1B6 | $1.4B6 | |
| Accounts payable | $2.9M8 | $7.2M12 | $9.3M9 | $5.2M6 | $30.2M6 | ||
| Current liabilities | $4.4M7 | $8.8M8 | $19.5M12 | $31.8M9 | $54.0M6 | $91.2M6 | |
| Total liabilities | $6.6M7 | $8.8M8 | $19.5M12 | $31.8M9 | $72.0M6 | $164.4M6 | |
| Retained earnings | -$78.2M8 | -$160.1M12 | -$286.3M9 | -$547.1M6 | -$972.4M6 | ||
| Shareholders’ equity | -$17.3M7 | -$31.3M8 | $285.0M9 | $463.0M6 | $700.6M6 | $1.1B6 | $1.2B6 |
Leadership
Who has led Nuvalent, Inc., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
2025
- Chief financial officerAlexandra Balcom Jul 28, 2021 to now14
Board members and other officers (21)
- OfficerBenjamin Lane Mar 20, 2026 to now15
- Chief Scientific OfficerHenry E. Pelish Jul 11, 2024 to now16
- Chief Medical OfficerChristopher Durant Turner Jul 28, 2021 to now17
- OfficerDarlene Noci Jul 28, 2021 to now18
- Board memberChristy J. Oliger Jun 20, 2025 to now19
- Board memberRon Squarer Dec 11, 2025 to now20
- Board memberGrant C. Bogle Dec 9, 2024 to now21
- Board memberEmily Conley Feb 3, 2022 to Aug 27, 202422
- Board memberAnna Protopapas Mar 31, 2022 to now23
- Board memberMichael L. Meyers Oct 6, 2022 to now24
- Board memberAndrew A. F. Hack Jul 28, 2021 to Dec 13, 202425
- Board memberCameron Wheeler Jul 28, 2021 to now26
- Board memberDwight Gary Gilliland Jul 28, 2021 to Jun 14, 202427
- Board memberJames E. Flynn Jul 28, 2021 to now28
- Board memberJoseph Pearlberg Jul 28, 2021 to now29
- Board memberMatthew Shair Jul 28, 2021 to now30
- Board memberMgmt Hif L.p. Deerfield Jul 28, 2021 to now28
- Board memberMgmt L.p. Deerfield Iv. Jul 28, 2021 to now28
- Board memberRobert Bowers Jackson Jul 28, 2021 to Jul 30, 202131
- Board memberSapna Srivastava Jul 28, 2021 to now32
- General counselDeborah Ann Miller Jul 28, 2021 to now33
Timeline
- Jan 25, 2017Founded Nuvalent, Inc. is founded2
Filings
524 filings to the SEC since October 2021: 5 annual reports, 14 quarterly reports, 54 major events, 297 insider forms, 29 large holders, 125 other. The latest 20:
- Jul 27, 202615-12G EDGAR
- Jul 17, 2026SCHEDULE 13G/A EDGAR
- Jul 17, 20264 EDGAR
- Jul 15, 20264 EDGAR
- Jul 15, 20264 EDGAR
- Jul 15, 20264 EDGAR
- Jul 15, 20264 EDGAR
- Jul 15, 20264 EDGAR
- Jul 15, 20264 EDGAR
- Jul 15, 20264 EDGAR
- Jul 15, 20264 EDGAR
- Jul 15, 20264 EDGAR
- Jul 15, 20264 EDGAR
- Jul 15, 20264 EDGAR
- Jul 15, 20264 EDGAR
- Jul 15, 20264 EDGAR
- Jul 15, 20264 EDGAR
- Jul 15, 2026POSASR EDGAR
- Jul 15, 2026S-8 POS EDGAR
- Jul 15, 2026S-8 POS EDGAR
The 524 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
229 open-market trades by officers, directors and large owners since October 2021: 2 buys and 227 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 9, 2026 | Pelish Henry E.Chief Scientific Officer | Sale | 2,111 | $123.81 | $261.4K | Form 4 |
| Jul 6, 2026 | Porter James RichardPresident and CEO | Sale | 30,000 | $123.72 | $3.7M | Form 4 |
| Jul 1, 2026 | Noci DarleneChief Development Officer | Sale | 23,000 | $123.59 | $2.8M | Form 4 |
| Jul 1, 2026 | Balcom AlexandraChief Financial Officer | Sale | 11,430 | $123.58 | $1.4M | Form 4 |
| Jun 29, 2026 | Noci DarleneChief Development Officer | Sale | 5,500 | $123.51 | $679.3K | Form 4 |
| Jun 9, 2026 | Noci DarleneChief Development Officer | Sale | 20,000 | $122.81 | $2.5M | Form 4 |
| Jun 8, 2026 | Porter James RichardPresident and CEO | Sale | 30,000 | $88.53 | $2.7M | Form 4 |
| Jun 1, 2026 | Balcom AlexandraChief Financial Officer | Sale | 11,430 | $98.69 | $1.1M | Form 4 |
| May 28, 2026 | Miller Deborah AnnChief Legal Officer | Sale | 5,500 | $107.84 | $593.1K | Form 4 |
| May 28, 2026 | Noci DarleneChief Development Officer | Sale | 5,500 | $107.80 | $592.9K | Form 4 |
| May 4, 2026 | Porter James RichardPresident and CEO | Sale | 30,000 | $101.69 | $3.1M | Form 4 |
| May 1, 2026 | Balcom AlexandraChief Financial Officer | Sale | 11,430 | $99.00 | $1.1M | Form 4 |
| Apr 30, 2026 | Miller Deborah AnnChief Legal Officer | Sale | 5,500 | $99.22 | $545.7K | Form 4 |
| Apr 29, 2026 | Noci DarleneChief Development Officer | Sale | 5,500 | $99.55 | $547.5K | Form 4 |
| Apr 9, 2026 | Pelish Henry E.Chief Scientific Officer | Sale | 3,093 | $104.48 | $323.2K | Form 4 |
| Apr 6, 2026 | Porter James RichardPresident and CEO | Sale | 30,000 | $103.77 | $3.1M | Form 4 |
| Apr 1, 2026 | Balcom AlexandraChief Financial Officer | Sale | 11,430 | $105.21 | $1.2M | Form 4 |
| Mar 30, 2026 | Noci DarleneChief Development Officer | Sale | 5,500 | $97.81 | $537.9K | Form 4 |
| Mar 26, 2026 | Miller Deborah AnnChief Legal Officer | Sale | 5,500 | $98.73 | $543.0K | Form 4 |
| Mar 25, 2026 | Balcom AlexandraChief Financial Officer | Sale | 13,700 | $100.16 | $1.4M | Form 4 |
All 229 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- James E. FlynnSCHEDULE 13G/A, 8 filings Feb 11, 2022 to Jul 17, 202634
- FMR LLCSCHEDULE 13G/A, 5 filings Feb 9, 2022 to Jul 8, 202635
- VANGUARD GROUP INCSCHEDULE 13G/A, 3 filings Feb 13, 2024 to Mar 27, 202636
- PERCEPTIVE ADVISORS LLCSC 13G/A, 2 filings Jan 2, 2024 to Nov 14, 202437
- Paradigm Biocapital Advisors LPSC 13G/A, 3 filings Oct 30, 2023 to Nov 14, 202438
- BlackRockSC 13G, 2 filings Oct 24, 2024 to Nov 8, 202439
- Bain Capital Life Sciences Fund II, L.P.SC 13D/A, 3 filings Nov 3, 2022 to Mar 29, 202440
- Fairmount Funds Management LLCSC 13G/A, 3 filings Nov 9, 2022 to Feb 14, 202441
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARNuvalent, Inc. filings on SEC EDGAR
- 2
- 3SEC EDGARNuvalent, Inc. 10-K for fiscal 2025
- 4SEC EDGARNuvalent, Inc. filings on SEC EDGAR
- 5
- 6SEC EDGARNuvalent, Inc. 10-K for fiscal 2025
- 7SEC EDGARNuvalent, Inc. 10-K for fiscal 2020
- 8SEC EDGARNuvalent, Inc. 10-K for fiscal 2021
- 9SEC EDGARNuvalent, Inc. 10-K for fiscal 2022
- 10SEC EDGARNuvalent, Inc. 10-Q for fiscal 2025
- 11SEC EDGARNuvalent, Inc. 10-Q for fiscal 2025
- 12SEC EDGARNuvalent, Inc. 10-K for fiscal 2022
- 13SEC EDGARNuvalent, Inc. 10-Q for fiscal 2025
- 14
- 15SEC EDGARBenjamin Lane, Officer
- 16
- 17
- 18SEC EDGARDarlene Noci, Officer
- 19SEC EDGARChristy J. Oliger, Board member
- 20SEC EDGARRon Squarer, Board member
- 21SEC EDGARGrant C. Bogle, Board member
- 22SEC EDGAREmily Conley, Board member
- 23SEC EDGARAnna Protopapas, Board member
- 24SEC EDGARMichael L. Meyers, Board member
- 25SEC EDGARAndrew A. F. Hack, Board member
- 26SEC EDGARCameron Wheeler, Board member
- 27SEC EDGARDwight Gary Gilliland, Board member
- 28SEC EDGARJames E. Flynn, Board member
- 29SEC EDGARJoseph Pearlberg, Board member
- 30SEC EDGARMatthew Shair, Board member
- 31SEC EDGARRobert Bowers Jackson, Board member
- 32SEC EDGARSapna Srivastava, Board member
- 33SEC EDGARDeborah Ann Miller, General counsel
- 34
- 35
- 36
- 37
- 38
- 39SEC EDGARBlackRock SC 13G on Nuvalent, Inc.
- 40
- 41